Puerarin 6''-O-xylosideCAS# 114240-18-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 114240-18-5 | SDF | Download SDF |
| PubChem ID | 100990912 | Appearance | Powder |
| Formula | C26H28O13 | M.Wt | 548.49 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Synonyms | 4',7-Dihydroxyisoflavone 8-C-(6''-xylosylglucoside) | ||
| Solubility | Soluble in methan | ||
| Chemical Name | 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]chromen-4-one | ||
| SMILES | C1C(C(C(C(O1)OCC2C(C(C(C(O2)C3=C(C=CC4=C3OC=C(C4=O)C5=CC=C(C=C5)O)O)O)O)O)O)O)O | ||
| Standard InChIKey | YCFQXQCEEPCZMO-KATYHMCLSA-N | ||
| Standard InChI | InChI=1S/C26H28O13/c27-11-3-1-10(2-4-11)13-7-36-24-12(18(13)30)5-6-14(28)17(24)25-22(34)21(33)20(32)16(39-25)9-38-26-23(35)19(31)15(29)8-37-26/h1-7,15-16,19-23,25-29,31-35H,8-9H2/t15-,16-,19+,20-,21+,22-,23-,25+,26+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Puerarin 6''-O-xyloside possesses significant anti-osteoporotic activity on ovariectomy mice, it has significant antitumour activities, the mechanisms are related to increased levels of caspase-3, caspase-7, caspase-9 and Bax, and reduced levels Bcl-2. |
| Targets | Bcl-2/Bax | Caspase |
| In vitro | In vitro and in vivo antitumour activities of puerarin 6″-O-xyloside on human lung carcinoma A549 cell line via the induction of the mitochondria-mediated apoptosis pathway.[Pubmed: 26730946]Pharm Biol. 2016 Sep;54(9):1793-9.Pueraria lobata (Leguminoseae) shows cytotoxic effects against cancer cells; however, its active components remain unclear. This study investigated the antitumour activity of puerarin 6″-O-xyloside (POS) on the human lung carcinoma A549 cell line. |
| In vivo | Anti-osteoporotic activity of puerarin 6″-O-xyloside on ovariectomized mice and its potential mechanism.[Pubmed: 25857587]Pharm Biol. 2015 Apr 10:1-7.Osteoporosis is one of the most common bone diseases, and radix of Pueraria lobata (Willd.) Ohwi possesses an obvious therapeutical effect on postmenopausal osteoporosis.
This study investigates the anti-osteoporotic activity of the puerarin 6"-O-xyloside (PXY) on ovariectomized mice and its related mechanism.
|
Puerarin 6''-O-xyloside Dilution Calculator
Puerarin 6''-O-xyloside Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8232 mL | 9.1159 mL | 18.2319 mL | 36.4637 mL | 45.5797 mL |
| 5 mM | 0.3646 mL | 1.8232 mL | 3.6464 mL | 7.2927 mL | 9.1159 mL |
| 10 mM | 0.1823 mL | 0.9116 mL | 1.8232 mL | 3.6464 mL | 4.558 mL |
| 50 mM | 0.0365 mL | 0.1823 mL | 0.3646 mL | 0.7293 mL | 0.9116 mL |
| 100 mM | 0.0182 mL | 0.0912 mL | 0.1823 mL | 0.3646 mL | 0.4558 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- PAOPA
Catalog No.:BCC6353
CAS No.:114200-31-6
- Z-Ala-OH
Catalog No.:BCC3055
CAS No.:1142-20-7
- Butyraxanthone B
Catalog No.:BCN3603
CAS No.:1141754-81-5
- Kuguacin N
Catalog No.:BCN3056
CAS No.:1141453-73-7
- Kuguacin J
Catalog No.:BCN3055
CAS No.:1141453-65-7
- Tirandalydigin
Catalog No.:BCN1860
CAS No.:114118-91-1
- Cabozantinib malate (XL184)
Catalog No.:BCC4388
CAS No.:1140909-48-3
- Ibandronic acid
Catalog No.:BCC5204
CAS No.:114084-78-5
- Humantenidine
Catalog No.:BCN4754
CAS No.:114027-39-3
- 16-Epivoacarpine
Catalog No.:BCN3940
CAS No.:114027-38-2
- Phaclofen
Catalog No.:BCC6562
CAS No.:114012-12-3
- Phenformin
Catalog No.:BCC9120
CAS No.:114-86-3
- CI 976
Catalog No.:BCC7299
CAS No.:114289-47-3
- Soyacerebroside I
Catalog No.:BCN6022
CAS No.:114297-20-0
- Guanosine Hydrate
Catalog No.:BCC5326
CAS No.:1143525-19-2
- AZD5363
Catalog No.:BCC1073
CAS No.:1143532-39-1
- TAK 21d
Catalog No.:BCC5609
CAS No.:1143578-94-2
- Fmoc-D-Leu-OH
Catalog No.:BCC3511
CAS No.:114360-54-2
- PF-8380
Catalog No.:BCC1857
CAS No.:1144035-53-9
- WYE-125132 (WYE-132)
Catalog No.:BCC4608
CAS No.:1144068-46-1
- Beta-Furoyleupatolide
Catalog No.:BCN6407
CAS No.:114437-24-0
- BNP (1-32), human
Catalog No.:BCC1039
CAS No.:114471-18-0
- Oroxin B
Catalog No.:BCN1203
CAS No.:114482-86-9
- Z-Ser-OH
Catalog No.:BCC2743
CAS No.:1145-80-8
In vitro and in vivo antitumour activities of puerarin 6''-O-xyloside on human lung carcinoma A549 cell line via the induction of the mitochondria-mediated apoptosis pathway.[Pubmed:26730946]
Pharm Biol. 2016 Sep;54(9):1793-9.
Context Pueraria lobata (Leguminoseae) shows cytotoxic effects against cancer cells; however, its active components remain unclear. Objective This study investigated the antitumour activity of puerarin 6''-O-xyloside (POS) on the human lung carcinoma A549 cell line. Materials and methods The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to determine the cytotoxicity of POS (at 10, 20 and 40 muM) in vitro, and xenograft nude mice were established to evaluate the antitumour effect of POS (at 40 mg/kg/d) in vivo by 15 days intraperitoneal injection (ip). To explore its mechanism of action, flow cytometry was performed to determine the pro-apoptotic effect of POS (at 10, 20 and 40 muM). Subsequently, the expression of caspase-3, caspase-7, caspase-9, Bcl-2 and Bax in A549 cells were determined. Results POS showed significant cytotoxicity toward A549 cells (p < 0.05) by inducing apoptosis. Treatment with POS significantly upregulated the levels of caspase-3 (p < 0.01), caspase-7 (p < 0.01), caspase-9 (p < 0.01) and Bax (p < 0.01) in A549 cells, and Bcl-2 was downregulated (p < 0.01). Additionally, the in vivo animal study showed that POS significantly inhibited tumour growth in A549 cells (p < 0.01). Conclusion Our study demonstrated the POS has significant antitumour activities. The mechanisms are related to increased levels of caspase-3, caspase-7, caspase-9 and Bax, and reduced levels Bcl-2.
Anti-osteoporotic activity of puerarin 6"-O-xyloside on ovariectomized mice and its potential mechanism.[Pubmed:25857587]
Pharm Biol. 2016;54(1):111-7.
CONTEXT: Osteoporosis is one of the most common bone diseases, and radix of Pueraria lobata (Willd.) Ohwi possesses an obvious therapeutical effect on postmenopausal osteoporosis. OBJECTIVE: This study investigates the anti-osteoporotic activity of the puerarin 6"-O-xyloside (PXY) on ovariectomized mice and its related mechanism. MATERIALS AND METHODS: Osteoporotic mice model was established by ovariectomy (OVX). A total of 50 mice were divided into five groups (n = 10): sham, OVX group, PXY treatment groups (20, 40, and 60 mg/kg/d, i.p.). After 12 weeks' treatment, body weights were recorded. Then, mice were sacrificed, and serum samples were collected to determine the blood calcium, blood phosphorus, alkaline phosphatase (ALP), and osteoprotegerin (OPG) concentrations and uterine index was assayed. The thigh-bones of mice were collected to evaluate histopathological changes. In the in vitro experiment, the effect of PXY on osteoblasts' proliferation was evaluated and western blotting was performed to determine expressions of OPG and the receptor activators of NF-kappaB ligand (RANKL), as well as the ratio of OPG/RANKL. RESULTS: PXY (40 and 60 mg/kg/d, i.p.) obviously decreased body weights and increased uterine index of OVX (p < 0.05), and improved osteoporotic syndromes of OVX mice; PXY also significantly increased the concentrations of blood calcium, blood phosphorus, ALP, and OPG of OVX mice (p < 0.05); moreover, PXY obviously up-regulated the ratio of OPG/RANKL (p < 0.05). CONCLUSION: Our results demonstrated that the puerarin 6"-O-xyloside possesses significant anti-osteoporotic activity on ovariectomy mice.
